Aardvark Therapeutics, Inc. Common Stock Price & Performance (AARD)

Aardvark Therapeutics (NASDAQ:AARD) has drawn significant investor interest after four insiders purchased $23.42 million worth of stock during its February IPO. Despite a 28% stock decline since its debut, analysts maintain optimism, assigning strong buy ratings and price targets as high as $30.50, reflecting confidence in its lead drug ARD-101.12

Aardvark Therapeutics, a clinical-stage biopharma company, saw insider purchases totaling over $23 million in February. Amid a declining stock price, experts remain optimistic about its lead drug, ARD-101, targeting metabolic disorders. Analysts from Morgan Stanley and BofA Securities have set price targets of $29 and $22, respectively.34

San Diego-based Aardvark Therapeutics raised $94 million in its February IPO, showcasing investor confidence. The funds will support advanced trials of ARD-101, targeting rare metabolic conditions. Despite recent stock volatility, the company’s innovative approach to hunger suppression positions it as a notable player in the biopharma sector.56